Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Mochida Files in Japan for PAH Drug Tyvaso DPI
Mochida Pharmaceutical said on April 30 that it has filed for approval in Japan for its pulmonary arterial hypertension (PAH) therapy MD-712, an inhalation powder version of treprostinil sold overseas as Tyvaso DPI. The product — administered using a dedicated…
To read the full story
Related Article
- Mochida Bags Japan Rights to United Therapeutics’ Tyvaso DPI
November 1, 2024
- Mochida Gets Japan Distribution Rights to Tyvaso
March 29, 2017
BUSINESS
- Eylea Bio-AG Snags 60% Share in Just 3 Months, Outpacing Biosimilar
May 29, 2026
- FRONTEO, Scohia Team Up on AI-Driven Indication Discovery
May 29, 2026
- AGC Biologics Launches Bispecific Antibody CDMO Project in Japan
May 28, 2026
- Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
- Asahi Kasei Licenses ADC Technology from Noguchi Institute
May 28, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…